Fairvoy Private Wealth LLC Has $316,000 Stock Position in AstraZeneca PLC $AZN

Fairvoy Private Wealth LLC reduced its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 8.0% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 4,529 shares of the company’s stock after selling 394 shares during the period. Fairvoy Private Wealth LLC’s holdings in AstraZeneca were worth $316,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Larson Financial Group LLC grew its holdings in shares of AstraZeneca by 297.9% during the 1st quarter. Larson Financial Group LLC now owns 386 shares of the company’s stock worth $28,000 after purchasing an additional 289 shares in the last quarter. FNY Investment Advisers LLC acquired a new stake in shares of AstraZeneca during the 1st quarter worth $29,000. Costello Asset Management INC acquired a new stake in shares of AstraZeneca during the 1st quarter worth $29,000. Highline Wealth Partners LLC grew its holdings in shares of AstraZeneca by 447.4% during the 1st quarter. Highline Wealth Partners LLC now owns 416 shares of the company’s stock worth $31,000 after purchasing an additional 340 shares in the last quarter. Finally, Maseco LLP acquired a new stake in AstraZeneca in the second quarter valued at about $34,000. 20.35% of the stock is owned by institutional investors and hedge funds.

AstraZeneca Price Performance

AstraZeneca stock opened at $85.31 on Friday. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $264.58 billion, a PE ratio of 32.07, a P/E/G ratio of 1.54 and a beta of 0.36. AstraZeneca PLC has a 12 month low of $61.24 and a 12 month high of $85.50. The stock has a 50-day moving average price of $78.04 and a two-hundred day moving average price of $73.10.

AstraZeneca (NASDAQ:AZN) last posted its earnings results on Tuesday, July 29th. The company reported $1.09 EPS for the quarter, meeting the consensus estimate of $1.09. The firm had revenue of $14.46 billion during the quarter, compared to the consensus estimate of $14.08 billion. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.The business’s quarterly revenue was up 16.1% on a year-over-year basis. During the same period last year, the company earned $1.24 earnings per share. Analysts expect that AstraZeneca PLC will post 4.51 EPS for the current year.

AstraZeneca Cuts Dividend

The company also recently announced a semi-annual dividend, which was paid on Monday, September 8th. Shareholders of record on Friday, August 8th were given a $0.505 dividend. The ex-dividend date was Friday, August 8th. This represents a yield of 200.0%. AstraZeneca’s dividend payout ratio (DPR) is currently 37.97%.

Wall Street Analysts Forecast Growth

AZN has been the topic of several research analyst reports. Berenberg Bank set a $97.00 price objective on AstraZeneca in a research note on Wednesday, July 9th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of AstraZeneca in a research note on Saturday, September 27th. Four research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $86.00.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.